HAE vs. ALGN, MMSI, ICUI, XRAY, QDEL, NEOG, STAA, CERS, OSUR, and ANIK
Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include Align Technology (ALGN), Merit Medical Systems (MMSI), ICU Medical (ICUI), DENTSPLY SIRONA (XRAY), QuidelOrtho (QDEL), Neogen (NEOG), STAAR Surgical (STAA), Cerus (CERS), OraSure Technologies (OSUR), and Anika Therapeutics (ANIK). These companies are all part of the "health care supplies" industry.
Haemonetics vs.
Align Technology (NASDAQ:ALGN) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.
Align Technology has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
In the previous week, Haemonetics had 1 more articles in the media than Align Technology. MarketBeat recorded 8 mentions for Haemonetics and 7 mentions for Align Technology. Align Technology's average media sentiment score of 0.69 beat Haemonetics' score of 0.07 indicating that Align Technology is being referred to more favorably in the media.
88.4% of Align Technology shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 0.6% of Align Technology shares are held by company insiders. Comparatively, 1.8% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Align Technology has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
Align Technology has a net margin of 11.15% compared to Haemonetics' net margin of 9.10%. Haemonetics' return on equity of 22.67% beat Align Technology's return on equity.
Align Technology presently has a consensus target price of $268.20, indicating a potential upside of 19.61%. Haemonetics has a consensus target price of $108.78, indicating a potential upside of 47.74%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts clearly believe Haemonetics is more favorable than Align Technology.
Align Technology received 391 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 69.74% of users gave Align Technology an outperform vote while only 61.43% of users gave Haemonetics an outperform vote.
Summary
Align Technology beats Haemonetics on 11 of the 18 factors compared between the two stocks.
Get Haemonetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Haemonetics Competitors List
Related Companies and Tools
This page (NYSE:HAE) was last updated on 1/20/2025 by MarketBeat.com Staff
